LAPTM4A

Across TCGA pan-cancer cohorts, LAPTM4A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LAPTM4A data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher LAPTM4A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LAPTM4A expression acts as an unfavorable survival marker.

KIRC, LUSC, and HNSC are the cancer types where LAPTM4A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.067	0.874	<.001	36	view →
LUSC	OS	Median	All	0.170	0.675	.025	15	view →
HNSC	DFS	Median	All	0.098	0.710	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LAPTM4A–KIRC (OS)

Open the KIRC breakdown →